Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Galderma

- PMLiVE

Galderma’s Nemluvio shows sustained improvements in moderate-to-severe atopic dermatitis

Up to 91% of patients achieved at least 75% improvement in eczema severity and up to 67% achieved near-complete skin clearance

- PMLiVE

Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance

Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood

- PMLiVE

Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms

Some patients found the treatment reduced itch and sleep disturbance within just two days

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

Galderma shares positive long-term data for Nemluvio in prurigo nodularis

The chronic skin disorder is estimated to affect up to 181,000 people in the US

- PMLiVE

Galderma shares positive two-year results for Nemluvio in atopic dermatitis

The chronic inflammatory skin disease affects more than 230 million people worldwide

- PMLiVE

MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

EU flag

EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha

EU flag

CHMP recommends Galderma’s nemolizumab for atopic dermatitis and prurigo nodularis

The drug has been recommended for use in patients with moderate-to-severe cases of the skin diseases

- PMLiVE

Galderma announces positive late-stage results for nemolizumab in prurigo nodularis

The chronic skin condition is estimated to affect up to 181,000 people in the US

- PMLiVE

FDA approves Galderma’s IL-31 inhibitor Nemluvio to treat prurigo nodularis in adults

The chronic skin condition is estimated to affect up to 181,000 people in the US

- PMLiVE

Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial

The condition affects more than 70 out of every 100,000 adults aged 18 to 64 years in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links